BR112016008288A2 - receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas - Google Patents

receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas

Info

Publication number
BR112016008288A2
BR112016008288A2 BR112016008288A BR112016008288A BR112016008288A2 BR 112016008288 A2 BR112016008288 A2 BR 112016008288A2 BR 112016008288 A BR112016008288 A BR 112016008288A BR 112016008288 A BR112016008288 A BR 112016008288A BR 112016008288 A2 BR112016008288 A2 BR 112016008288A2
Authority
BR
Brazil
Prior art keywords
treatment
receptor
autoimmune diseases
soluble gamma
amdb
Prior art date
Application number
BR112016008288A
Other languages
English (en)
Inventor
Ter Meer Dominik
Sondermann Peter
Ludwig Ralf
Original Assignee
Suppremol Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suppremol Gmbh filed Critical Suppremol Gmbh
Publication of BR112016008288A2 publication Critical patent/BR112016008288A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

a presente invenção refere-se genericamente ao campo da biotecnologia e medicina. ela proporciona um agente, uma composição farmacêutica e um estojo para o tratamento de doenças autoimunes bolhosas (amdb). mais especificamente, a invenção refere-se ao uso de um receptor fc gama solúvel para o tratamento de amdb e a uma composição farmacêutica e um estojo que compreende o referido receptor. a presente invenção refere-se ainda a um método de tratamento de amdb.
BR112016008288A 2013-10-16 2013-10-16 receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas BR112016008288A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2013/071599 WO2015055240A1 (en) 2013-10-16 2013-10-16 Soluble fc gamma receptor for treatment of autoimmune bullous diseases

Publications (1)

Publication Number Publication Date
BR112016008288A2 true BR112016008288A2 (pt) 2017-09-26

Family

ID=49596237

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016008288A BR112016008288A2 (pt) 2013-10-16 2013-10-16 receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas

Country Status (13)

Country Link
US (1) US9981009B2 (pt)
EP (1) EP3057606B1 (pt)
JP (1) JP2016539920A (pt)
KR (1) KR102138219B1 (pt)
CN (1) CN105873600B (pt)
AU (1) AU2013403046B2 (pt)
BR (1) BR112016008288A2 (pt)
CA (1) CA2927263C (pt)
EA (1) EA034176B1 (pt)
IL (1) IL245116B (pt)
MX (1) MX371137B (pt)
NZ (1) NZ719745A (pt)
WO (1) WO2015055240A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2796144A1 (en) * 2013-04-26 2014-10-29 SuppreMol GmbH Highly concentrated Formulations of soluble Fc receptors
CN105873600B (zh) 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1006183A1 (en) * 1998-12-03 2000-06-07 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Recombinant soluble Fc receptors
DE10157290A1 (de) * 2001-11-22 2003-06-05 Max Planck Gesellschaft Pharmazeutische Zusammensetzung enthaltend sFcRgamma IIb oder sFcRgamma III
US8187593B2 (en) * 2002-08-14 2012-05-29 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
CN101001872A (zh) * 2004-04-16 2007-07-18 宏观基因有限公司 FcγRIIB－特异性抗体及其使用方法
US7655229B2 (en) * 2004-09-02 2010-02-02 Chan Andrew C Anti-FC-gamma RIIB receptor antibody and uses therefor
EP1870422A1 (en) 2006-06-20 2007-12-26 SuppreMol GmbH Means for the treatment of diseases characterized by an excessive immune reaction
EP2161031A1 (en) * 2008-09-05 2010-03-10 SuppreMol GmbH Fc gamma receptor for the treatment of B cell mediated multiple sclerosis
US10028998B2 (en) * 2012-10-30 2018-07-24 Suppremol Gmbh Method for treating an inflammatory disease and/or an autoimmune disease with a soluble FcγRIIb
CN105873600B (zh) 2013-10-16 2019-11-05 苏伯利莫尔公司 用于自身免疫性大疱病治疗的可溶性Fcγ受体

Also Published As

Publication number Publication date
CN105873600B (zh) 2019-11-05
WO2015055240A1 (en) 2015-04-23
EA034176B1 (ru) 2020-01-14
MX2016004799A (es) 2016-07-26
AU2013403046A1 (en) 2016-05-26
IL245116A0 (en) 2016-06-30
CN105873600A (zh) 2016-08-17
AU2013403046B2 (en) 2020-02-06
JP2016539920A (ja) 2016-12-22
MX371137B (es) 2020-01-17
KR102138219B1 (ko) 2020-07-28
IL245116B (en) 2019-09-26
CA2927263A1 (en) 2015-04-23
CA2927263C (en) 2022-12-13
NZ719745A (en) 2018-10-26
US9981009B2 (en) 2018-05-29
KR20160061430A (ko) 2016-05-31
EP3057606B1 (en) 2020-03-11
EP3057606A1 (en) 2016-08-24
US20160235814A1 (en) 2016-08-18
EA201690766A1 (ru) 2016-07-29

Similar Documents

Publication Publication Date Title
BR112016029334A2 (pt) produto farmacêutico, uso de um anticorpo, kit, método para tratar um paciente com câncer e métodos e usos de novos produtos
BR112018076601A2 (pt) formulação farmacêutica oral, métodos para tratar um paciente, e, uso de uma formulação
CL2018000542A1 (es) Nuevos derivados de fenoximetilo.
BR112018010720A8 (pt) agonistas do receptor de apelina e métodos de uso
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
BR112012021275A2 (pt) composição, formulação, e, uso de uma formulação.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
BR112016012146A2 (pt) Compostos derivados de aminopiridina como inibidores quinase da família tam, composição farmacêutica compreendendo ditos compostos e uso terapêutico dos mesmos
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
CO2017002472A2 (es) Formulación de acetato de abiraterona
EA201691808A1 (ru) Кортикостероидные композиции для местного применения
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112015019873A2 (pt) inibidores macrocíclicos da lrrk2 cinase
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
CL2015001187A1 (es) Compuestos derivados de azaquinolin-carboxamida, como inhibidores de p70s6k; su metodo de manufactura; composicion farmaceutica que los comprende; y su uso para el tratamiento profilactico o terapeutico de trastornos hiperproliferativos, cancer, retinopatia diabetica, dolor, eczema y degeneracion macular relacionada con la edad, entre otras enfermedades.
EA201791225A1 (ru) Композиции и способы применения солабегрона с модифицированным высвобождением при симптомах нижних мочевых путей
BR112017025553A2 (pt) composição de vacina, e kit
AU2015278731B2 (en) Fused triterpene compounds and uses thereof
BR112017014416A2 (pt) sal de mangiferina-6-o-berberina e método de preparação e uso do mesmo
BR112015024703A2 (pt) formulação farmacêutica, método de tratamento e/ou prevenção de restenose e kit para o tratamento e/ou prevenção de restenose
CR20160353A (es) Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
BR112017027721A2 (pt) formulação de alta concentração

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.